Dogwood Therapeutics (DWTX) AI Stock Analysis

• Market Cap: $93.64M
• Dividend Yield: N/A
• Average Volume (3M): 1.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.49
• Revenue Growth: N/A
• EPS Growth: -295.27%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -8.20
• Shares Outstanding: 29,727,865
• 10 Day Avg. Volume: 77,367
• 30 Day Avg. Volume: 1,536,657
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.29
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.28K
• Enterprise Value/Ebitda: -3.05
• 1Y Price Target: $21.00
• Price Target Upside: 415.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $3.00 ▼(-26.29% Downside)

The score is pressured primarily by deteriorating financial performance (widening losses and rising cash burn) and a clearly bearish technical trend (below all major moving averages with negative MACD). A low-leverage balance sheet and positive strategic corporate developments provide some support, but do not offset the current loss/cash-burn profile and weak price action.

Positive Factors

Low leverage / solid equity base

Very low leverage and a sizable equity cushion materially reduce near-term bankruptcy and refinancing risk for this R&D-stage biotech. That balance-sheet flexibility supports ongoing Phase 2 execution, strategic licensing or M&A options, and provides multi-month runway advantages versus highly leveraged peers.

Positive Phase 2b interim efficacy signal

An independent interim review showing treatment separation versus placebo is a structural de-risking event for the Halneuron program. A favorable Phase 2b signal increases probability of positive topline results and regulatory engagement, improving the program's long-term commercial and partnering prospects.

Pipeline diversification and non-dilutive funding

Acquiring SP16 and securing NCI-funded Phase 1b diversifies Dogwood's pipeline beyond Halneuron and brings a first-in-class mechanism. NCI funding reduces near-term cash requirements and validates the science, strengthening strategic optionality and reducing dependence on equity raises over the next several quarters.

Negative Factors

No commercial revenue; rising losses

Persisting zero revenue and sharply wider losses reflect an extended pre-commercial profile and increasing burn to support trials. Continued negative earnings will erode equity absent funding or milestone receipts, raising structural financing needs and investor dilution risk over the medium term.

Accelerating cash burn and negative cash flow

Operating cash flow deterioration signals heavier near-term funding needs to complete pivotal studies. Negative and accelerating cash burn constrains the company's ability to self-fund development programs, making execution dependent on external financing or partnerships, which can delay milestones if capital access tightens.

Near-term dilution and equity issuance risk

Shareholder approvals, increased equity incentive reserves and issuance tied to the SP16 license materially raise potential dilution. With ongoing losses and funding needs, structural reliance on equity issuance or stock-based deals can dilute existing holders and affect governance and control dynamics over the coming quarters.

Dogwood Therapeutics Business Overview & Revenue Model

Company Description

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

How the Company Makes Money

Dogwood Therapeutics generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company engages in strategic partnerships with larger pharmaceutical firms to co-develop and market its therapies, often receiving upfront payments, milestone payments, and royalties on sales. Additionally, Dogwood Therapeutics may secure funding through research grants and collaborations with academic institutions, contributing to its R&D efforts. Licensing agreements for its proprietary technologies and intellectual property serve as another significant revenue stream, allowing the company to monetize its innovations while expanding its market reach.

Dogwood Therapeutics Financial Statement Overview

Summary

Dogwood Therapeutics exhibits typical characteristics of early-stage biotech firms with no revenue and significant losses. While it has a strong equity base and low leverage, the company's financial health is heavily reliant on external financing, posing a risk if revenue generation does not commence soon.

Income Statement

Dogwood Therapeutics has consistently reported no revenue over the years, which is typical for early-stage biotechnology firms. The company has significant net losses, indicating high R&D and operational costs with no offsetting income. The lack of revenue and consistent losses are concerning, but expected in this sector.

Balance Sheet

The company's balance sheet shows a strong equity base and low leverage, with a Debt-to-Equity Ratio of 0, indicating no debt burden. However, equity is primarily financed by cash injections, reflecting a reliance on external funding. This suggests a stable but potentially unsustainable financial structure without revenue generation.

Cash Flow

Dogwood Therapeutics has negative free cash flow, which reflects its cash burn typical in biotech. The Operating Cash Flow to Net Income Ratio indicates efficient cash management relative to reported losses. However, continued reliance on financing activities to sustain operations could pose long-term risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-29.43K	-12.18K	0.00	0.00	0.00	0.00
EBITDA	-31.62M	-12.25M	-5.45M	-12.32M	-15.64M	-10.01M
Net Income	-38.20M	-12.35M	-5.30M	-12.25M	-15.96M	-10.35M
Balance Sheet
Total Assets	91.99M	94.31M	4.17M	8.37M	15.78M	31.47M
Cash, Cash Equivalents and Short-Term Investments	10.13M	14.85M	3.32M	7.03M	14.01M	29.80M
Total Debt	174.78K	15.59M	0.00	0.00	0.00	0.00
Total Liabilities	14.61M	30.03M	358.55K	1.04M	1.28M	1.53M
Stockholders Equity	77.39M	64.28M	3.81M	7.33M	14.50M	29.94M
Cash Flow
Free Cash Flow	-18.11M	-8.79M	-4.87M	-11.47M	-15.69M	-3.90M
Operating Cash Flow	-18.11M	-8.79M	-4.87M	-11.47M	-15.69M	-3.90M
Investing Cash Flow	3.76M	3.76M	0.00	0.00	0.00	0.00
Financing Cash Flow	22.57M	16.70M	1.16M	4.49M	-97.60K	33.38M

Dogwood Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DWTX, the sentiment is Negative. The current price of 4.07 is below the 20-day moving average (MA) of 5.00, below the 50-day MA of 5.60, and below the 200-day MA of 5.21, indicating a bearish trend. The MACD of -0.65 indicates Positive momentum. The RSI at 26.20 is Positive, neither overbought nor oversold. The STOCH value of 12.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DWTX.

Dogwood Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRKR	49 Neutral	$34.51M	―	-110.67%	―	-12.99%	-13.67%
BOLT	49 Neutral	$11.15M	-0.26	-81.97%	―	-46.88%	34.83%
SNSE	46 Neutral	$13.95M	-0.52	-67.47%	―	―	9.63%
DWTX	45 Neutral	$93.64M	-0.13	-97.54%	―	―	-295.27%
ACXP	45 Neutral	$6.86M	-0.34	-291.07%	―	―	61.10%
BRTX	44 Neutral	$10.65M	-0.79	-207.73%	―	1.70%	-111.67%

Dogwood Therapeutics Corporate Events

Dogwood Therapeutics Approves Equity Plan Amid Business Merger

On November 21, 2025, Dogwood Therapeutics, Inc. held a special meeting where stockholders approved the Second Amended and Restated Equity Incentive Plan, increasing the shares reserved for issuance significantly. This approval, alongside the conversion of Series A, A-1, and A-2 Non-Voting Convertible Preferred Stock, facilitated the completion of a business combination with Sealbond Limited, marking a strategic move in the company’s growth and compliance with Nasdaq Listing Rules.

The most recent analyst rating on (DWTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Dogwood Therapeutics stock, see the DWTX Stock Forecast page.